Rbc Life Sciences 8 K Form (Page 4 of 5) in pdf

EXHIBIT 99.1

Press Release

For Further Information:

For Immediate Release

Richard S. Jablonski, VP, CFO

Tel: 972-893-4000

RBC Life Sciences Reports Third Quarter 2012 Results

Irving, Texas, November 8, 2012 - RBC Life Sciences, Inc. (OTCQB: RBCL) (the “Company), a

provider of proprietary nutritional supplements, and wound care and pain management products, today

reported consolidated net sales of $6.7 million for the quarter ended September 30, 2012, compared to

$7.1 million for the third quarter of 2011. For the quarter, the Company reported a net loss of $323,216,

or $0.01 per share, compared to a net loss of $289,850, or $0.01 per share, for the same quarter in 2011.

“In the third quarter of 2012, sales of our medical products decreased due in part to the Chapter 11

reorganization of a major customer. Also, sales of nutritional products were unfavorably impacted by a

decrease in the number of new Associates that were recruited in 2012,” said RBC Life Sciences CEO,

Clinton H. Howard. “Some of the decrease we experienced was offset by improved sales to our

international licensees, and we continue to be encouraged by the sales of our best-selling dietary

supplement product, Stem-Kine

. Stem-Kine is a unique dietary supplement that has been shown in two

published human clinical studies to nutritionally support bone marrow and other stem-cell-producing

tissues, enabling them to increase their production of stem cells. Stem cells form the natural repair and

renewal system of the body.

About RBC Life Sciences

Through wholly owned subsidiaries, RBC Life Sciences develops, markets and distributes high-quality

nutritional supplements and personal care products under its RBC Life brand to a growing population of

consumers seeking wellness and a healthy lifestyle. Through its wholly owned subsidiary,

MPM

Medical,

the Company also develops and markets to health care professionals in the United States proprietary

prescription and nonprescription products for advanced wound care and pain management. All products

are tested for quality assurance in-house, and by outside independent laboratories, to comply with

regulations in the U.S. and in more than thirty countries in which the products are distributed. For more

information, visit the company's website at

The statements above, other than statements of historical fact, may be forward-looking. Actual events will

be dependent upon a number of factors and risks including, but not limited to, changes in plans by the

Company's management, delays or problems in production, changes in the regulatory process, changes in

market trends, and a number of other factors and risks described from time to time in the Company's

filings with the Securities and Exchange Commission

Rbc Life Sciences 8 K Form Page 4